B-cell non-hodgkin lymphoma: A case-based discussion of recent advances in patient management

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 7, 2010, Pages 1-15

  Czuczman, Myron S ^a   Gregory, Stephanie A ^b   van Der Jagt, Richard ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; BENDAMUSTINE; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; IBRITUMOMAB TIUXETAN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; OFATUMUMAB; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEMSIROLIMUS; TRIAMCINOLONE ACETATE; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL DISEASE; ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; ARTICLE; BLOATING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPHADENOPATHY; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PROGNOSIS; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 77956108221     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
2. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27:1492-1501.
3. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204-210.
4. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378-4384.
5. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106-114.
6. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010;10:21-27.
7. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood. 2008; 112. Abstract 330.
8. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) as first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood. 2009;114. Abstract 205.
9. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
10. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114. Abstract 405.
11. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
12. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood. 2009;114. Abstract 933.
13. ClinicalTrials.gov. Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma. Identifier: NCT00433537. Available at: clinicaltrials.gov/ct2/show/NCT00433537. Accessed June 15, 2010.
14. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26: 5156-5164.
15. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003). Blood. 2009; 114. Abstract 1676.
16. Vacirca JL, Acs PI, Shimkus BJ, Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. Abstract presented at: American Society of Hematology Annual Meeting. Chicago, IL: June 4-8, 2010. Abstract 8041.
17. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28:2902-2913.
18. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol. 2010; 28. Abstract 8004.
19. Cortazar P, Keegan P, Justice RL, Johnson JR, Pazdur R. Targeted cancer therapies: FDA approval overview. J Clin Oncol. 2010; 28. Abstract 2537.
20. In focus: ECOG 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Adv Hematol Oncol. 2004;2:152.
21. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570.
22. Gregory SA, Leonard JP, Vose JM, et al. Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2005; 23(16 suppl):575s. Abstract 6561.
23. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood. 2009; 114. Abstract 933.
24. Theocharous P, Shpilberg O, Elsayed YA. A randomized, open-label, multicenter phase II study of bortezomib with fludarabine in comparison to rituximab with fludarabine in follicular lymphoma subjects previously treated with rituximab. J Clin Oncol. 2010; 28(15S). Abstract TPS303.
25. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106-114.
26. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009; 114. Abstract 405.
27. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
28. Osterborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 328.
29. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003). Blood. 2009; 114. Abstract 1676.
30. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;26:4285-4292.
31. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26: 2717-2724.
32. Chavez J, Walsh M, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Classification of newly diagnosed diffuse large B-cell lymphoma (DLBCL) according to the Han's criteria defines two groups of patients with different clinical outcomes following systemic rituximab-multi agent anthracycline-based therapy. Blood. 2009;114. Abstract 623.
33. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-3365.
34. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21:1046-1052.
35. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26: 2519-2525.
36. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
37. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
38. Rigacci L, Puccini B, Orciuolo E, et al. Safety and efficacy of bendamustine with or without rituximab for the treatment of heavily pretreated CLL and lymphoma patients: a multicenter retrospective study. Blood. 2009;114. Abstract 1662.
39. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114. Abstract 405.
40. Vacircal JL, Acs PI, Shimkus BJ, Rosen PJ. Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2010; 28. Abstract 8041.
41. Sanchez-Gonzalez B, Penalver F, Guillen H, et al. Clinical experience of bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma subjects previously treated with rituximab. J Clin Oncol. 2010; 28. Abstract e18526.